The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients

BACKGROUND: We aimed to test whether the prognostic value of 18 F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic castration-resistant prostate cancer (mCRPC) extends to the estimation of systemic treatment response duration. METHODS: mCRPC patients sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauckneht, Matteo, Bertagna, Francesco, Donegani, Maria Isabella, Durmo, Rexhep, Miceli, Alberto, De Biasi, Vincenzo, Laudicella, Riccardo, Fornarini, Giuseppe, Berruti, Alfredo, Baldari, Sergio, Versari, Annibale, Giubbini, Raffaele, Sambuceti, Gianmario, Morbelli, Silvia, Albano, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616756/
https://www.ncbi.nlm.nih.gov/pubmed/34012060
http://dx.doi.org/10.1038/s41391-021-00391-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616756/
https://www.ncbi.nlm.nih.gov/pubmed/34012060
http://dx.doi.org/10.1038/s41391-021-00391-8

Ejemplares similares